AMR Action Fund Announces First Investments in Adaptive Phage Therapeutics and Venatorx Pharmaceuticals

  05 April 2022

The AMR Action Fund, the world’s largest public-private partnership investing in biotech companies that are developing antibiotics, announced today that it has invested in Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals. The transactions mark the Fund’s first investments and are an important step toward its goals of bringing to market new treatments for priority pathogens identified by the World Health Organization (WHO) and U.S. Centers for Disease Control and Prevention.

Further reading: AMR action fund
Author(s): AMR action fund
Smart Innovations  


Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition


JSS University

Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!